Ozmosi | Potassium canrenoate Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Potassium canrenoate

Pronounced as: poh-TAS-ee-um kan-REN-oh-ate

Alternative Names: potassium canrenoate
Clinical Status: Active
Latest Update: 2026-02-13
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Aldosterone Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous, Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | Czech | France | Poland | Slovenia | Taiwan | United Kingdom

Approved Indications: None

Company: AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Potassium canrenoate

Countries in Clinic: France, Greece

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Ischemic Stroke

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2025-522796-28-00

 GEN-100

P2

Withdrawn

Ischemic Stroke

2027-06-30

2024-513809-31-00

 2019PI117

P2

Not yet recruiting

Unknown

2033-06-05

2025-05-02

Treatments

Recent News Events

Date

Type

Title

04/23/2024

PubMed

 Establishing and Validating an Innovative Focal Adhesion-Linked Gene Signature for Enhanced Prognostic Assessment in Endometrial Cancer.

10/12/2023

PubMed

 Spironolactone Eyedrop Favors Restoration of Corneal Integrity after Wound Healing in the Rat.

10/11/2023

PubMed

 Potassium canrenoate in brain-dead organ donors: a randomised controlled clinical trial protocol (CANREO-PMO).

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions